Cargando…
Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612289/ https://www.ncbi.nlm.nih.gov/pubmed/26523271 http://dx.doi.org/10.3350/cmh.2015.21.3.279 |
_version_ | 1782396155389280256 |
---|---|
author | An, Chansik Choi, Youn Ah Choi, Dongil Paik, Yong Han Ahn, Sang Hoon Kim, Myeong-Jin Paik, Seung Woon Han, Kwang-Hyub Park, Mi-Suk |
author_facet | An, Chansik Choi, Youn Ah Choi, Dongil Paik, Yong Han Ahn, Sang Hoon Kim, Myeong-Jin Paik, Seung Woon Han, Kwang-Hyub Park, Mi-Suk |
author_sort | An, Chansik |
collection | PubMed |
description | BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC. |
format | Online Article Text |
id | pubmed-4612289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-46122892015-10-30 Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease An, Chansik Choi, Youn Ah Choi, Dongil Paik, Yong Han Ahn, Sang Hoon Kim, Myeong-Jin Paik, Seung Woon Han, Kwang-Hyub Park, Mi-Suk Clin Mol Hepatol Original Article BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC. The Korean Association for the Study of the Liver 2015-09 2015-09-30 /pmc/articles/PMC4612289/ /pubmed/26523271 http://dx.doi.org/10.3350/cmh.2015.21.3.279 Text en Copyright © 2015 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article An, Chansik Choi, Youn Ah Choi, Dongil Paik, Yong Han Ahn, Sang Hoon Kim, Myeong-Jin Paik, Seung Woon Han, Kwang-Hyub Park, Mi-Suk Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title_full | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title_fullStr | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title_full_unstemmed | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title_short | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
title_sort | growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612289/ https://www.ncbi.nlm.nih.gov/pubmed/26523271 http://dx.doi.org/10.3350/cmh.2015.21.3.279 |
work_keys_str_mv | AT anchansik growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT choiyounah growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT choidongil growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT paikyonghan growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT ahnsanghoon growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT kimmyeongjin growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT paikseungwoon growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT hankwanghyub growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease AT parkmisuk growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease |